MA31150B1 - Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade - Google Patents

Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade

Info

Publication number
MA31150B1
MA31150B1 MA32085A MA32085A MA31150B1 MA 31150 B1 MA31150 B1 MA 31150B1 MA 32085 A MA32085 A MA 32085A MA 32085 A MA32085 A MA 32085A MA 31150 B1 MA31150 B1 MA 31150B1
Authority
MA
Morocco
Prior art keywords
vegf
adjuvant
treatment
specific antagonists
neoadjuvant therapy
Prior art date
Application number
MA32085A
Other languages
English (en)
Inventor
Napoleone Ferrara
Nina Korsisaari
Robert D Mass
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31150B1 publication Critical patent/MA31150B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de traitement de tumeurs bénignes, précancéreuses ou non métastatiques utilisant un antagoniste spécifique anti-vegf. L'invention concerne également des procédés de traitement d'un sujet risquant de développer des tumeurs bénignes, précancéreuses ou non métastatiques utilisant un antagoniste spécifique anti-vegf. L'invention concerne également des procédés de traitement ou de prévention de la récurrence d'une tumeur en utilisant un antagoniste spécifique anti-vegf ainsi que l'utilisation d'antagonistes spécifiques de vegf dans une thérapie du cancer par néoadjuvant et adjuvant.
MA32085A 2006-12-19 2009-07-09 Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade MA31150B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US87074506P 2006-12-19 2006-12-19
US87074106P 2006-12-19 2006-12-19
US87726706P 2006-12-27 2006-12-27
US91963807P 2007-03-22 2007-03-22
US95838407P 2007-07-05 2007-07-05
US98939707P 2007-11-20 2007-11-20
PCT/US2007/088000 WO2008077077A2 (fr) 2006-12-19 2007-12-18 Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade

Publications (1)

Publication Number Publication Date
MA31150B1 true MA31150B1 (fr) 2010-02-01

Family

ID=39323719

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32085A MA31150B1 (fr) 2006-12-19 2009-07-09 Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade

Country Status (28)

Country Link
US (6) US20080248033A1 (fr)
EP (2) EP2101807B1 (fr)
JP (4) JP2010513566A (fr)
KR (5) KR20140148491A (fr)
CN (1) CN103143017A (fr)
AR (1) AR064458A1 (fr)
AU (1) AU2007333735A1 (fr)
BR (1) BRPI0720552A2 (fr)
CA (1) CA2671734A1 (fr)
CO (1) CO6210829A2 (fr)
CR (1) CR10940A (fr)
DK (1) DK2101807T3 (fr)
EC (1) ECSP099523A (fr)
ES (1) ES2582656T3 (fr)
HK (1) HK1133210A1 (fr)
HU (1) HUE029445T2 (fr)
IL (1) IL238913A0 (fr)
MA (1) MA31150B1 (fr)
MX (1) MX2009006779A (fr)
MY (1) MY183404A (fr)
NO (1) NO20092604L (fr)
NZ (1) NZ578472A (fr)
PL (1) PL2101807T3 (fr)
RU (1) RU2013129450A (fr)
SG (2) SG10201503407WA (fr)
SI (1) SI2101807T1 (fr)
TW (2) TWI577695B (fr)
WO (1) WO2008077077A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717431A2 (pt) * 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
DK3216803T3 (da) 2008-06-25 2020-06-02 Novartis Ag Stabile og opløselige antistoffer, der hæmmer vegf
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010059969A2 (fr) * 2008-11-22 2010-05-27 Genentech, Inc. Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2010091234A2 (fr) * 2009-02-06 2010-08-12 The General Hospital Corporation Procédés de traitement de lésions vasculaires
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
JP2012524083A (ja) * 2009-04-20 2012-10-11 ジェネンテック， インコーポレイテッド アジュバント癌治療
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2781519A1 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes proteiques contenant une super-helice et/ou une attache et leurs utilisations
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
WO2011094722A1 (fr) 2010-02-01 2011-08-04 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de la tyrosine kinase pour le traitement de la maladie de cushing et l'hypercortisolisme
WO2011094716A1 (fr) * 2010-02-01 2011-08-04 Cedars-Sinai Medical Center Utilisation d'inhibiteurs de la tyrosine kinase pour le traitement du prolactinome
JP6017964B2 (ja) 2010-03-01 2016-11-02 ティーエーユー・セラピューティクス・エルエルシー 癌診断および撮像
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012010546A1 (fr) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Biomarqueurs du plasma sanguin pour des polythérapies à base de bevacizumab, dans le traitement du cancer du pancréas
MX340558B (es) 2010-08-24 2016-07-14 F Hoffmann-La Roche Ag * Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
WO2012135624A1 (fr) * 2011-04-01 2012-10-04 The Trustees Of The University Of Pennsylvania Traitement du cancer du côlon au moyen d'inhibiteurs du complément
WO2012151574A1 (fr) 2011-05-05 2012-11-08 Duke University Procédés pour mettre au point un pronostic du cancer du pancréas et prédire la réponse à une thérapie contre le cancer
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
SG11201400526TA (en) * 2011-09-12 2014-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
US8858941B2 (en) 2011-09-23 2014-10-14 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US20130142796A1 (en) * 2011-12-05 2013-06-06 Subhransu Ray Treatment for angiogenic disorders
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014001325A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Méthode de fabrication de conjugués d'anticorps à région fc comprenant au moins une entité de liaison qui se lie spécifiquement à une cible et leurs utilisations
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
EP2914961A4 (fr) 2012-10-31 2016-04-20 Oncomed Pharm Inc Méthodes et surveillance d'un traitement par un antagoniste de dll4
US10460831B2 (en) 2012-12-03 2019-10-29 Koninklijke Philips N.V. Predictive outcome assessment for chemotherapy with neoadjuvant bevacizumab
EP3424530A1 (fr) 2013-03-15 2019-01-09 Zyngenia, Inc. Complexes multispécifiques monovalents et multivalents et leurs utilisations
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
WO2016087416A1 (fr) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Anticorps multispécifiques
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
JP2019506602A (ja) * 2015-12-30 2019-03-07 ヴィジョンゲイト，インコーポレーテッド 異形成を自動的に検出しモニターし、化学予防を施行するためのシステム及び方法
US11499973B2 (en) 2016-05-17 2022-11-15 Duke University Methods of predicting responsiveness of a cancer to a VEGF targeting agent and methods of prognosing and treating cancer
JP2021506861A (ja) 2017-12-19 2021-02-22 アコーオス インコーポレイテッド 内耳への治療用抗体のａａｖ媒介送達
US11026649B2 (en) * 2018-06-25 2021-06-08 Siemens Medical Solutions Usa, Inc. Method and system for determining tumor burden in medical images
EP3927736A4 (fr) * 2019-02-18 2022-12-28 Agency For Science, Technology And Research Leurre flt-1 lié à une membrane et ses utilisations
TW202110431A (zh) * 2019-05-17 2021-03-16 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
WO2021226444A2 (fr) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Pièges et mini-pièges de vegf et procédés de traitement de troubles oculaires et de cancers
CN112773852A (zh) * 2021-03-16 2021-05-11 宁夏医科大学 一种对细胞有保护作用的中草药组合物的制备工艺
CN113512589B (zh) * 2021-07-14 2023-03-10 复旦大学附属中山医院 Prune1基因检测在多发性骨髓瘤患者预后中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1493825A3 (fr) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Procédé pour la production de ligands constitués par des acides nucléiques
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0617706B1 (fr) 1991-11-25 2001-10-17 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6458939B1 (en) 1996-03-15 2002-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1695985T3 (da) 1997-04-07 2011-06-14 Genentech Inc Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CA2372053C (fr) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions et procedes de traitement du cancer par inhibition selective de vegf
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP2001072587A (ja) * 1999-07-01 2001-03-21 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2005001486A1 (fr) 2003-06-06 2005-01-06 Genentech, Inc. Modulation de l'interaction chaine hgf beta/c-met
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050044853A1 (en) * 2003-09-02 2005-03-03 Kazutora Yoshino Ecology system
MXPA06014421A (es) * 2004-06-10 2007-05-04 Regeneron Pharma Uso de inhibidores de vegf para el tratamiento de cancer humano.
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
BRPI0513534A (pt) * 2004-07-20 2008-05-06 Genentech Inc inibidores de proteìna 4 semelhante à angiopoietina, combinações, e seu uso

Also Published As

Publication number Publication date
CR10940A (es) 2009-08-13
TW201525003A (zh) 2015-07-01
US20110052576A1 (en) 2011-03-03
CA2671734A1 (fr) 2008-06-26
CO6210829A2 (es) 2010-10-20
DK2101807T3 (en) 2016-08-29
WO2008077077A2 (fr) 2008-06-26
US20120148584A1 (en) 2012-06-14
JP2010513566A (ja) 2010-04-30
NZ578472A (en) 2012-06-29
EP3095455A1 (fr) 2016-11-23
WO2008077077A3 (fr) 2008-08-14
US20140178363A1 (en) 2014-06-26
HUE029445T2 (en) 2017-02-28
JP2013189452A (ja) 2013-09-26
TWI577695B (zh) 2017-04-11
PL2101807T3 (pl) 2016-11-30
SI2101807T1 (sl) 2016-08-31
KR20140031996A (ko) 2014-03-13
RU2013129450A (ru) 2015-01-10
HK1133210A1 (zh) 2010-03-19
AR064458A1 (es) 2009-04-01
KR20130060309A (ko) 2013-06-07
SG176448A1 (en) 2011-12-29
NO20092604L (no) 2009-09-18
BRPI0720552A2 (pt) 2014-01-07
TW200831538A (en) 2008-08-01
US20180208647A1 (en) 2018-07-26
KR20090097188A (ko) 2009-09-15
ECSP099523A (es) 2009-09-29
MY183404A (en) 2021-02-18
CN103143017A (zh) 2013-06-12
JP2015110609A (ja) 2015-06-18
IL238913A0 (en) 2015-06-30
US20080248033A1 (en) 2008-10-09
MX2009006779A (es) 2009-08-27
KR20140148491A (ko) 2014-12-31
KR20150097813A (ko) 2015-08-26
ES2582656T3 (es) 2016-09-14
AU2007333735A2 (en) 2009-11-05
AU2007333735A1 (en) 2008-06-26
EP2101807A2 (fr) 2009-09-23
US20160108116A1 (en) 2016-04-21
JP2018052939A (ja) 2018-04-05
EP2101807B1 (fr) 2016-05-25
SG10201503407WA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
NO20084546L (no) Diagnostikk og behandlinger for tumorer
DK1893196T3 (da) Diarylhydantoin-forbindelse
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
WO2009015050A3 (fr) Profil d'expression génique pour prédire la survie d'une patiente atteinte d'un cancer des ovaires
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
HUP0302332A2 (hu) Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
TW200615268A (en) Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
BR112013008140A2 (pt) "compostos imidazotriazinona".
WO2008027837A3 (fr) Potentialisateur de petite molécule utilisé en hormonothérapie pour le cancer du sein
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DE602006012013D1 (de) Proteasom-hemmer und verwendungsverfahren dafür
WO2006015079A3 (fr) Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
WO2004067570A3 (fr) Diagnostic et traitement du cancer de la prostate
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MXPA05011171A (es) Metodos y composiciones que activan cinasas de tirosina para el diagnostico y tratamiento de osteoartritis.
MX2007005501A (es) Asociacion tumoral de mieloide de lectina-1 asociada a dap12 y metodos.
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
WO2005003776A3 (fr) Procede in vitro pour la detection du cancer du rein
WO2008063773A3 (fr) Traitement combinatoire avec les molécules inhibitrices du récepteur du facteur de croissance épidermique et le gène-7 associé à la différenciation des mélanomes